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Introduction: The Eastern Cooperative Oncology Group (ECOG) 
4599 study showed a significant survival benefit with the use of beva-
cizumab (BV) in combination with carboplatin and paclitaxel (CP) in 
comparison with CP chemotherapy alone in patients with previously 
untreated advanced, metastatic or recurrent non–small-cell lung can-
cer (NSCLC). Such results were achieved using BV as maintenance 
therapy until progressive disease. Because current data on single-agent 
BV maintenance in non–small-cell lung cancer are limited, we present 
a retrospective analysis of safety and efficacy outcomes for patients 
who received maintenance BV after induction treatment and the main-
tenance-eligible population of the control arm in ECOG 4599.
Methods: Landmark analyses were conducted in patients in both the 
CP and CP+BV groups who were alive and progression free through 
the completion of six cycles + 21 days. The BV maintenance population 
consisted of patients in the CP+BV arm, who were alive without progres-
sive disease before the start of maintenance (maintenance-nonprogressor 
population). CP nonprogressors were those patients in the CP-alone arm 
without progressive disease after six cycles of CP + 21 days.
Results: Two hundred and seventeen patients (51%) were alive, progres-
sion free, and eligible for maintenance therapy six cycles + 21 days after 
induction CP+ BV compared with 134 patients (30%) in the CP-alone 
arm. Postinduction progression-free survival was significantly longer in 
the BV maintenance group relative to CP nonprogressors (4.4 versus 
2.8 months; hazards ratio [HR] 0.64; p < 0.001). One-year overall sur-
vival rates were 75% for the BV maintenance group versus 69% in the 
CP nonprogressor group. Two-year overall survival rates were 34% for 
the BV maintenance group versus 25% in the CP nonprogressor group. 
Median postinduction overall survival (OS) was also significantly lon-
ger for the BV-maintenance group compared with CP nonprogressors 
(12.8 versus 11.4 months; HR 0.75; p = 0.030). Within the subgroup 
having complete response or partial response after induction, the pro-
gression-free survival and OS hazard ratio estimates were 0.59 (95% 
[confidence interval] CI: 0.41–0.84) and 0.78 (95% CI: 0.53–1.14), 
respectively. In the maintenance setting, BV was associated with a less-
than 1% rate of grade 3 or 4 hematological toxicities, no grade 3 or 4 
nausea, vomiting or diarrhea, and no grade 5 toxicities.
Conclusions: In this retrospective analysis of patients in the ECOG 
4599 study, who were alive, progression free, and on-study 21 days 
after six cycles of induction therapy, significant reductions in HRs for 
progression (0.64, p < 0.001) and survival (0.75, p = 0.03) were asso-
ciated with BV treatment during induction and maintenance com-
pared with CP induction therapy alone and suggestive of possible 
benefit because of bevacizumab maintenance.
(J Thorac Oncol. 2012;7: 1707–1712)
Lung cancer is the leading cause of cancer-related death in the United States and worldwide.1 Although modest progress 
has been made with the use of chemotherapy in patients 
with metastatic lung cancer, additional treatment options are 
needed. Given the preponderant role it plays in tumor growth 
and development, angiogenesis has become an important 
therapeutic target in lung cancer.2,3 Bevacizumab (BV; Avastin, 
Genentech, South San Francisco, CA) is a recombinant, 
humanized monoclonal antibody against vascular endothelial 
growth factor (VEGF), a critical factor in tumor angiogenesis.4 
The Eastern Cooperative Oncology Group (ECOG) 4599 study, 
a phase III randomized controlled trial, compared the efficacy 
and safety of the use of carboplatin and paclitaxel (CP) alone 
or in combination with BV in patients with nonsquamous cell, 
stage IIIB to IV non–small-cell lung cancer (NSCLC).5 Median 
progression-free survival (PFS) was significantly improved in 
the CP+BV arm (6.2 versus 4.5 months; hazard ratio [HR] = 0.66; 
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p < 0.0001) and median overall survival (OS), the primary 
endpoint, was also significantly increased in the CP+BV arm 
(12.3 versus 10.3 months; HR = 0.79; p = 0.003).The results 
of this trial led to the Food and Drug Administration approval 
of CP+BV for the treatment of patients with stage IIIB/IV 
nonsquamous NSCLC.
In the ECOG 4599 study, the significant survival bene-
fits observed in the CP+BV arm were achieved using BV both 
during induction and as maintenance therapy until progressive 
disease (PD). However, real-world data show divergent pat-
terns of BV use as maintenance therapy subsequent to CP+BV 
induction even though its antiangiogenic mechanism of action 
supports its continued use until PD.2 In addition, in preclini-
cal cancer models continuous VEGF suppression with BV has 
been shown to be key to tumor control.6–8 Furthermore, data 
from the GOG-218 trial, a randomized, double-blind, placebo-
controlled phase 3 trial of CP with or without BV in patients 
with stages III or IV ovarian cancer, strongly suggests that 
maintenance BV is associated with a significant improvement 
in PFS in this patient population.9 Because current data on sin-
gle-agent BV maintenance in NSCLC are limited, we present 
a retrospective analysis of safety and efficacy outcomes for 
patients who received maintenance BV after induction treat-
ment and the maintenance-eligible population of the control 
arm in ECOG 4599.
PATIENTS AND METHODS
ECOG 4599 Patients and Study Design
Full details of patient eligibility and clinical trial design 
for the ECOG 4599 trial have been previously described.5In 
brief, between July 2001 and April 2004, chemotherapy naïve 
patients with recurrent or advanced NSCLC (stage IIIB or 
IV) were randomized to CP chemotherapy alone or in com-
bination with BV. Other inclusion criteria included measur-
able disease, ECOG performance status (PS) of 0 or 1, and 
adequate hematologic, hepatic, and renal function. Patients 
with squamous cell histology, hemoptysis, or central nervous 
system metastases were excluded.
Randomized patients were stratified by the presence of 
measurable disease, prior radiotherapy, percentage weight loss 
(< 5%, ≥ 5%), and disease stage (IIIB not recurrent, IV not 
recurrent, and IV recurrent). Patients were randomly assigned 
to one of two treatment arms: (1) C (area under the curve = 
6 mg/mL, day 1), P (200 mg/m2, day 1), and BV (15 mg/kg, 
day 1), or (2) treatment with CP alone. Treatment cycles were 
repeated every 3 weeks, and tumor assessments were per-
formed every 6 weeks for 24 weeks, then every 9 weeks for 
the remainder of the treatment period, and then every 12 weeks 
after the completion of treatment. Patients in the CP cohort 
stopped chemotherapy after six cycles. Patients on CP+BV 
stopped chemotherapy after six cycles and continued on BV 
maintenance until disease progression. All tumor responses 
were determined using Random Evaluation Criteria In Solid 
Tumors, and toxicity was graded using the National Cancer 
Institute Common Terminology Criteria, version 2.0 (Cancer 
Therapy evaluation Program, April 30, 1999). The primary 
endpoint of the study was OS.
ECOG 4599 Maintenance BV 
Retrospective Statistical Analysis
Landmark analyses were conducted in patients in both 
the CP and CP+BV groups, who were alive and progression 
free through the completion of six cycles + 21 days. The land-
mark date was chosen to approximate the end of the induc-
tion period for both patient groups and the beginning of the 
seventh cycle of therapy for patients receiving BV mainte-
nance. The BV-maintenance population consisted of patients 
in the CP+BV arm without PD before the start of maintenance 
(maintenance-nonprogressor population). CP nonprogressors 
were those patients in the CP-alone arm without PD after six 
cycles of CP + 21 days.
Measuring PFS and OS from the landmark date rather 
than from the date of randomization eliminates the potential 
for lead-time bias that could be caused by variations in the tim-
ing of cycles among different patients. Response rates, PFS, 
OS, and 1-year survival rates were estimated using Kaplan–
Meier methods. HRs were based on a Cox model that adjusted 
for baseline factors including age, sex, race, ECOG PS, stage 
of disease, weight loss, disease histology, and best response to 
induction therapy.
RESULTS
Patient Disposition and Demographics
Between July 2001 and April 2004, 869 patients were 
randomized to treatment (Fig. 1). Among the 440 patients 
randomized to CP, 194 (44%) completed six cycles of induction 
therapy and 134 (30%) were alive and progression free at 
the landmark date. Among the 429 patients randomized to 
CP+BV, 258 (60%) completed six cycles of induction therapy 
and 217 (51%) were alive and progression free at the landmark 
date. Patient and disease characteristics were generally similar 
for the CP nonprogressor and BV-maintenance populations 
(Table 1). There was, however, a significantly (p = 0.003) larger 
proportion of patients whose best response through induction 
therapy was a complete response or partial response in the 
BV-maintenance group relative to patients in the CP group 
(57% versus 40%, respectively). Baseline factors significantly 
associated with a higher likelihood of completing six cycles of 
induction therapy and being alive and progression free at the 
landmark date were induction treatment with CP+BV rather 
than CP, ECOG PS 0 rather than 1, weight loss less than 5%, 
and adenocarcinoma histology.
Duration of Treatment and Safety
Among the 217 patients in the BV maintenance group, 
95%, 75%, 50%, and 25% completed 7 or more, 9 or more, 
12 or more, and 16 or more cycles of therapy from the start 
of induction, respectively. Ten of 217 patients (5%) who were 
eligible to receive BV maintenance treatment did not do so 
but were included in this analysis (intention-to-treat). The 
main reasons for BV discontinuation during maintenance 
were PD (70%) and toxicity (10%). Treatment-related grade 
3 to 5 adverse events (AEs) occurred more commonly during 
induction than postinduction, with generally lower incidence 
rates of grade 3 or 4 AEs during BV maintenance than during 
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CP+BV induction, and the spectrum of toxicities differing 
between these groups (Table 2).
Because only patients alive and progression free 21 days 
after completing six cycles of therapy were included in this 
analysis, there were no grade 5 toxicities during induction for 
either treatment group. Rates of treatment-related toxicities do 
not represent those seen in the full ECOG 4599 study popula-
tion and are generally more favorable.
Efficacy
Efficacy outcomes for patients in the CP nonprogressor 
and BV-maintenance groups are presented in Table 3. 
One hundred and sixty-two of 217 patients (75%) in the 
BV-maintenance group and 92 of 134 patients (69%) in the 
CP nonprogressor group were alive and on-study 1 year after 
the start of induction therapy. The 1-year PFS (32% versus 
17%) and 2-year OS (34% versus 25%) rates were also 
higher for the BV-maintenance population compared with CP 
nonprogressors.
The Kaplan–Meier PFS and OS curves shown in 
Figure 2 estimate only postinduction survival for the subset 
of ECOG 4599 patients who were alive and progression free 
21 days after six cycles of induction therapy. Postinduction 
PFS was significantly longer in the BV-maintenance group 
relative to CP nonprogressors (4.4 versus 2.8 months; HR 
0.64; p < 0.001). Median postinduction OS was also sig-
nificantly longer for the BV-maintenance group compared 
with CP nonprogressors (12.8 versus 11.4 months; HR 0.75; 
p = 0.030).
Median OS from start of induction was longer for the 
BV-maintenance group as compared with the CP nonpro-
gressors (17.0 versus 15.8 months). Within the subgroup 
having complete response or partial response, the PFS and 
OS hazard ratio estimates were 0.59 (95% CI: 0.41–0.84) 
and 0.78 (95% CI: 0.53–1.14), respectively. The sample size 
for patients having stable disease after induction was con-









(n = 351) pa
Age <70 yrs 102 (76) 165 (76) 267 (76) 0.986
Female sex 62 (46) 107 (49) 169 (48) 0.580
White, race 122 (91) 183 (84) 305 (87) 0.070
ECOG PS 0 vs. 1 69 (51) 97 (45) 166 (47) 0.216
Stage IIIB vs. IV 16 (12) 33 (15) 49 (14) 0.391
Weight loss <5% 105 (78) 175 (81) 280 (80) 0.604
Adenocarcinoma 99 (74) 161 (74) 260 (74) 0.948
Best induction response
 CR/PR 54 (40) 123 (57) 177 (50) 0.003
 SD 51 (38) 64 (29) 115 (33) 0.097
 Unknown 29 (22) 30 (14) 59 (17) —
aPearson test value for CP nonprogressor vs. BV-maintenance groups.
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DISCUSSION
In NSCLC, the significant survival benefits observed 
with BV+CP in the pivotal trial ECOG 4599 were achieved 
using BV therapy until PD.5 However, the overall effects of 
maintenance BV therapy have not been previously evaluated. 
In this retrospective analysis of patients in the ECOG 4599 
study, who were alive, progression free, and on-study 21 days 
after six cycles of induction therapy, significant reductions in 
hazard ratios for progression (0.64, p < 0.001) and survival 
(0.75, p = 0.03), suggestive of possible benefit because of BV 
maintenance were observed. Furthermore, at 1 and 2 years, 
75% and 34%, respectively, of patients in the BV-maintenance 
group were alive versus 69% and 25% respectively, in the CP 
group. It is also important to view these survival rates in the 
context of the larger number of patients who were alive and 
progression free by the sixth cycle + 21-day time point in 
the BV+CP group compared with the CP group alone (51% 
versus 30%, respectively). This suggests superiority of the 
BV+CP regimen in allowing patients to receive and poten-
tially benefit from maintenance therapy at the end of the 
induction phase.
These results are consistent with a recent retrospective 
analysis of the ARIES observational cohort study showing 
a potential benefit, in both OS and PFS, associated with 
maintenance BV beyond induction with first-line BV+CT.10 
In this trial, out of 1967 patients enrolled, 1215 (62%) were 
alive and progression free beyond their induction therapy. As 
measured from the initiation of BV+CP induction, median OS 
was 19.8 months for the BV-maintenance group versus 15.3 
months in the control arm, and median PFS was 9.2 versus 
7.9 months, respectively. Postinduction median OS was 15.7 
months for the BV-maintenance group (n = 539; 95% CI 14.3–
17.6; HR 0.71) versus 11.2 months (n = 674; 95% CI 10.1–
12.5) for the control arm, and median PFS was 5.1 versus 3.8 
months (HR = 0.77), respectively, also suggesting the potential 
benefit of BV maintenance in improving PFS and OS after 
treatment with induction BV+CP. Furthermore, data from this 
retrospective analysis of the ECOG 4599 are also consistent 
with results from the ATLAS trial, which investigated the 
use of BV ± erlotinib maintenance until disease progression 
in a selected nonprogressor population that received a 
BV-containing induction regimen.11–13 This was a phase IIIb, 
randomized, controlled multicenter trial conducted in patients 
with locally advanced, recurrent, or metastatic NSCLC. ATLAS 
was stopped early after a preplanned interim efficacy analysis 
because the primary endpoint of improved PFS had been met 
with a median of 4.8 months for the BV+erlotinib arm versus 
3.7 months for BV alone (HR = 0.71; p = 0.0006) as measured 
from the initiation of maintenance therapy. However, there was 
no difference in OS survival between the two arms (14.4 versus 
13.3 months, respectively; HR = 0.92; p = 0.57)(Fig. 3).13,14
In addition, results from this retrospective analysis 
highlight that BV has a predictable and manageable safety 
profile in patients with NSCLC, both in combination with 
first-line chemotherapy and when continued as maintenance 
therapy in patients without PD. As observed in Table 2, 
in the maintenance setting, BV was associated with a less-
than 1% rate of grade 3 or 4 hematological toxicities, no 
grade 3 or 4 nausea, vomiting or diarrhea, and no grade 5 
toxicities. Furthermore, the safety and tolerability of BV 
TABLE 2.  Summary of Grade 3–5 Adverse Events of Interest in ECOG 4599 by Treatment Group
Treatment-Related AE, %
Induction Therapya Postinduction Therapy
CP (n = 134) CP + BV (n = 217) BVb (n = 217)
Grade 3/4/5 Grade 3/4/5 Grade 3/4/5
Any 22.4/15.7/0 22.1/34.6/0 13.8/5.5/1.8
Febrile neutropenia 2.2/0/0 5.5/0/0 0.5/0/0
Infection with Gr 3 or 4 neutropenia 0.7/0/0 1.8/0.9/0 0.9/0/0
Sensory neuropathy 9.0/0/0 8.3/0.5/0 2.3/0/0
Motor neuropathy 0.7/0/0 0.9/0/0 1.4/0/0
Nausea 3.0/0/0 4.1/0/0 0/0/0
Diarrhea 0.7/0/0 1.8/0.5/0 0/0/0
Vomiting 3.0/0/0 3.2/0/0 0/0/0
Fatigue 6.0/0.7/NAc 6.5/0/NAc 3.2/0/NAc
Cardiovascular (arrhythmia) 0/0/0 0/0/0 0/0.5/0.5
Cardiac ischemia 0/0/0 0/0/0 0/0/0.5
Hypertension 0/0/0 4.6/0/0 1.8/0.5/0
Thrombosis/embolism 0/0/0 0.5/0/0 0.9/0.9/0
Dyspnea 0.7/0/0 3.2/0.5/0 0.5/0/0
Proteinuria 0/0/0 0.5/0/0 2.8/0.5/0
Hemorrhage, any toxicity 0/0/0 0.9/0/0 0.5/0.5/0.9
aThrough 6 cycles only.
bAEs for patients in the BV postinduction group are reported for patients receiving ≥7 cycles (n = 207).
cNot an option under CTCAE v3.0.
AE, adverse event; BV, bevacizumab; CP, carboplatin and paclitaxel.
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in the maintenance setting have been also highlighted in a 
recent analysis of SAIL, an international, multicenter, single-
arm trial investigating the safety of first-line bevacizumab 
in combination with standard chemotherapy in advanced 
NSCLC. In this trial, a low incidence of grade 3 or worse AEs 
was reported with the use of maintenance BV and the most-
common AEs were grade 1 to 2 epistaxis, hypertension, and 
proteinuria. Of particular note is that in this trial, the median 
time to progression was 8.9 months, and median OS was 
18.8 months for patients who received BV maintenance as 
measured from the initiation of induction BV+CP.15,16
Even though BV has not been formally studied as a 
single agent in patients with metastatic NSCLC, preclinical 
models have shown that inhibition of the VEGF signaling 
causes robust and early changes in endothelial cells, pericytes, 
and basement membrane of vessels such as loss of endothelial 
fenestrations, suppression of vascular sprouting, and ceasing 
of patency and blood flow in some vessels.6,17,18 In addition, in 
preclinical lung cancer models and in clinical settings, such as 
colorectal and ovarian cancers, continuous VEGF suppression 
with BV has been shown to be important for tumor control 
and survival.6–9 Given that no tumor responses are observed 
with the use of single-agent BV, its benefit in the maintenance 
setting may be associated with a tumor static effect mediated 
by its antiangiogenic properties.
The limitations of this analysis are its retrospective nature 
and that E4599 was not designed to address the role of main-
tenance bevacizumab in this setting. The primary objective of 
ECOG 4599 was to evaluate the efficacy of induction BV+CP 
with maintenance BV upon disease progression in compari-
son with standard-of-care CP alone. That said, these results 
suggest that BV maintenance is an important component of 
the regimen used in ECOG 4599 and that its use is associated 
with a beneficial effect in PFS and OS in patients that received 
induction BV+CP and that did not progress after six cycles of 
therapy. This concept is supported by the PFS and OS rates at 1 
and 2 years and the overall larger number of patients who can 
achieve these milestones compared with the CP arm.
FIGURE 2.  Kaplan–Meier estimates of (A) postinduction progression-free survival and (B) overall survival. Arrows indicate rates 
for patients at 1 year and at 2 years from the start of induction treatment (induction + postinduction periods). Numbers of 
patients at risk at designated time intervals are shown in this figure.
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In summary, the addition of BV to a standard, platinum-
based, two-agent chemotherapy regimen confers a significant 
improvement on OS, PFS, and response rate in patients 
with nonsquamous, non–small-cell carcinoma, and such an 
improvement was achieved using BV therapy until PD. In this 
retrospective analysis of patients in the ECOG 4599 study we 
found significant reductions in hazard ratios for progression 
and survival associated with maintenance BV treatment in 
patients who were alive, progression free, and on-study 21 
days after six cycles of induction therapy. These findings 
support the use of BV maintenance until disease progression 
as originally described in the landmark ECOG 4599 study.
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